Exagen Inc. Announces Select Preliminary 2025 Financial Results
01/11/2026 03:00 PM • Exagen Inc. (Nasdaq: XGN) announced preliminary 2025 financial results showing record full-year revenue of $66M-$67M, representing 19-20% year-over-year growth. The company achieved AVISE CTD test volume growth of 11% and trailing 12-month average selling price expansion of at least $30 compared to 2024. Year-end cash position strengthened to $32M, up $10M from 2024. CEO John Aballi highlighted strong execution across teams and recent platform enhancements despite ASP headwinds in the second half of the year.
XGN - Company reported record full-year revenue with 19-20% YoY growth, achieved 11% test volume growth, demonstrated ASP expansion of at least $30, increased cash position by $10M to $32M, launched platform enhancements, and strengthened scientific and commercial teams. CEO expressed confidence in execution and future strategy despite some mid-year ASP headwinds.